This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Anesthetics may modulate cancer surgical outcome: a possible role of miRNAs regulation
BMC Anesthesiology Open Access 09 March 2021
-
Regulatory mechanisms of B cell responses and the implication in B cell-related diseases
Journal of Biomedical Science Open Access 01 September 2019
-
Olea europaea small RNA with functional homology to human miR34a in cross-kingdom interaction of anti-tumoral response
Scientific Reports Open Access 17 August 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d′Etudes des Lymphomes de l′Adulte. Blood 2010; 116: 2040–2045.
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511.
Calin GA, Croce CM . MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857–866.
Zhang B, Pan X, Cobb GP, Anderson TA . MicroRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1–12.
Bader AG, Brown D, Winkler M . The promise of microRNA replacement therapy. Cancer Res 2010; 70: 7027–7030.
Craig VJ, Cogliatti SB, Imig J, Renner C, Neuenschwander S, Rehrauer H et al. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood 2011; 117: 6227–6236.
Rao DS, O'Connell RM, Chaudhuri AA, Garcia-Flores Y, Geiger TL, Baltimore D . MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity 2010; 33: 48–59.
Hoeller S, Schneider A, Haralambieva E, Dirnhofer S, Tzankov A . FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1. Histopathology 2010; 57: 73–80.
Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011; 19: 1116–1122.
Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92: 3152–3162.
Sarosiek KA, Malumbres R, Nechushtan H, Gentles AJ, Avisar E, Lossos IS . Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood 2010; 115: 570–580.
Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010; 70: 5923–5930.
Acknowledgements
We would like to thank Stephan Dirnhofer and Sergio Cogliatti for helpful discussions. This study was funded by grants from the Swiss Cancer League and the Zurich University Research Priority Program in Systems Biology to AM.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
AGB is an employee of Mirna Therapeutics, Inc., which develops miRNA-based therapeutics. All the other authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Craig, V., Tzankov, A., Flori, M. et al. Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia 26, 2421–2424 (2012). https://doi.org/10.1038/leu.2012.110
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.110
This article is cited by
-
p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target
Molecular Biology Reports (2023)
-
Anesthetics may modulate cancer surgical outcome: a possible role of miRNAs regulation
BMC Anesthesiology (2021)
-
Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR2 and miR-34a
Investigational New Drugs (2020)
-
Regulatory mechanisms of B cell responses and the implication in B cell-related diseases
Journal of Biomedical Science (2019)
-
Epstein−Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas
Leukemia (2019)